Streptococcus pneumoniae PPS-3 Specific Neutra™ Antibody Products

Are you grappling with lengthy antibody development timelines or challenges in generating functional antibodies against complex polysaccharide antigens? Creative Biolabs' S. pneumoniae PPS-3-specific neutra™ antibody products leverage advanced glycoengineering and hybridoma screening technologies to deliver highly specific, pre-validated neutralizing antibodies, empowering precise research and streamlined therapeutic development.

Introduction to Streptococcus pneumoniae PPS-3

S. pneumoniae remains a leading cause of invasive infections such as pneumonia, meningitis, and bacteremia, particularly in immunocompromised individuals. Its polysaccharide capsule, a critical virulence factor, enables immune evasion by masking surface antigens. Among over 100 serotypes, serotype 3 (PPS-3) is distinguished by its unique capsular structure and association with severe clinical outcomes.

Fig. 1 Increased virulence factors in serotype 3 strains.¹

• Structure

PPS-3 is a high-molecular-weight, zwitterionic polysaccharide composed of repeating units of glucose, galactose, and glucuronic acid. Its structural complexity arises from alternating α(1→3) and β(1→4) glycosidic linkages, forming a helical conformation that limits antigen accessibility. This architecture poses challenges for antibody recognition, necessitating antibodies with high conformational specificity.

• Related Signaling Pathways

PPS-3 mediates immune evasion by interfering with complement activation and phagocytosis. It binds to Factor H, a regulatory protein in the alternative complement pathway, inhibiting C3b deposition and opsonization. Additionally, PPS-3 activates inhibitory receptors on B cells (e.g., Siglec-5), suppressing antibody-mediated clearance. Neutralizing PPS-3 restores complement-mediated lysis and enhances opsonophagocytic killing.

• Associated Diseases

S. pneumoniae serotype 3 is linked to heightened morbidity in adults with chronic respiratory diseases, asplenia, or immunosenescence. It exhibits increased resistance to antibiotic therapies and higher mortality rates compared to other serotypes. Despite widespread vaccination, PPS-3 remains problematic due to suboptimal immune responses elicited by existing conjugate vaccines.

Applications of S. pneumoniae PPS-3 Neutralizing Antibodies

• Advancing Next-Generation Vaccines

Anti-PPS-3 antibodies are critical for assessing the immunogenicity of novel conjugate or protein-based vaccines. They enable precise measurement of antibody titers and functional activity in clinical trial samples, supporting correlate-of-protection analyses.

• Therapeutic Antibody Development

Monoclonal antibodies targeting PPS-3 offer a promising adjunct to antibiotics, particularly for high-risk groups. Preclinical studies demonstrate that these antibodies enhance bacterial clearance in pulmonary infection models, reducing bacterial load and inflammatory pathology.

• Diagnostic and Surveillance Tools

Rapid detection of PPS-3 in clinical specimens aids in serotype-specific surveillance, informing regional vaccine policies. The antibodies are compatible with lateral flow assays and multiplex bead arrays, enabling high-throughput serotyping in resource-limited settings.

• Mechanistic Research

Study PPS-3's interaction with host immune regulators using co-immunoprecipitation and surface plasmon resonance (SPR). These antibodies facilitate mapping of epitope-paratope interfaces to guide structure-based vaccine design.

Our Recombinant Antibodies Targeting PPS-3

Creative Biolabs' S. pneumoniae PPS-3-specific antibodies are rigorously validated for specificity and neutralizing activity. These antibodies target immunodominant epitopes within the capsular polysaccharide, disrupting Factor H binding and restoring complement activation. Our antibodies are optimized for ELISA, flow cytometry, and opsonophagocytic killing assays (OPKA), ensuring reproducibility across experimental platforms.

• Functional Assays: Quantify opsonophagocytic activity in vaccine efficacy studies.
• Serotyping: Confirm PPS-3 presence in clinical isolates via immunoassays.
• Therapeutic Development: Evaluate antibody-mediated bacterial clearance in preclinical models.

Creative Biolabs' S. pneumoniae PPS-3-specific neutra™ antibody products are engineered to overcome the challenges of polysaccharide-targeted research and development. With unmatched specificity and functional validation, these antibodies accelerate vaccine design, therapeutic discovery, and epidemiological surveillance. Consult our experts to explore tailored antibody solutions for your needs.

REFERENCE

1. Luck, Jennifer N., Hervé Tettelin, and Carlos J. Orihuela. "Sugar-coated killer: serotype 3 pneumococcal disease." Frontiers in Cellular and Infection Microbiology 10 (2020): 613287. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fcimb.2020.613287